이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Unity Biotechnology 과거 수익 실적

과거 기준 확인 0/6

Unity Biotechnology은 연평균 21.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 19.1%의 비율로 수입이 증가했습니다. 매출은 연평균 17.4%의 비율로 증가했습니다.

주요 정보

21.3%

수익 성장률

39.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	17.4%
자기자본 수익률	-152.9%
순이익	n/a
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

수익 및 비용 분석

Unity Biotechnology 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:UBX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	0	-30	16	-6
31 Mar 24	0	-40	18	0
31 Dec 23	0	-40	19	0
30 Sep 23	0	-35	19	11
30 Jun 23	0	-33	20	11
31 Mar 23	0	-31	19	0
31 Dec 22	0	-44	20	0
30 Sep 22	5	-56	21	0
30 Jun 22	5	-59	22	0
31 Mar 22	5	-64	23	-9
31 Dec 21	5	-61	23	0
30 Sep 21	0	-70	23	-54
30 Jun 21	0	-81	24	-35
31 Mar 21	0	-82	24	-11
31 Dec 20	0	-94	24	0
30 Sep 20	0	-92	24	125
30 Jun 20	0	-86	23	106
31 Mar 20	0	-91	22	90
31 Dec 19	0	-82	20	0
30 Sep 19	0	-86	19	0
30 Jun 19	0	-83	18	0
31 Mar 19	0	-79	17	0
31 Dec 18	0	-76	16	59
30 Sep 18	1	-67	14	0
30 Jun 18	1	-60	12	0
31 Mar 18	1	-52	11	0
31 Dec 17	1	-45	10	0

양질의 수익: UBX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: UBX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: UBX 은(는) 수익성이 없지만 지난 5년 동안 연간 19.3% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 UBX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: UBX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 0.5% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: UBX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -152.85% )을 갖습니다.

Unity Biotechnology 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Recent updates

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Price target decreased by 10% to US$6.00

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률